Copenhagen, April 4th, 2019 – MC2 Therapeutics A/S, a late clinical-stage company focused on topical therapies for chronic inflammatory conditions, today announced the appointment of Samia Kappe as Executive Vice President Sales & Marketing Europe.
Mrs. Kappe brings to MC2 Therapeutics more than 15 years of experience in commercialization of skin and wound care products. Mrs. Kappe has successfully launched topical products in EU and US, grown product franchises and transacted deals to build portfolios through a commitment to support patients and customers to experience a real difference by a sincere interest in their needs.
“Samia represents a strong insight in the dermatology market dynamics in Europe and in what matters in daily routines for people with chronic inflammatory conditions such as psoriasis and atopic dermatitis. She brings strategic perspective and operational experience that is extremely valuable to MC2 Therapeutics as the company continues to build a commercial infrastructure in US and EU aiming to launch first products within the next 12 months”, said Jesper J. Lange, President & CEO of MC2 Therapeutics adding that: “We had very encouraging clinical read outs in 2018 and are now expanding our team and efforts to ensure successful launches of a new standard of topicals based on our PAD™ Technology.”
In Q3 2018 MC2 Therapeutics announced very positive Ph3 data in a head-to-head trial against a leading branded comparator on its MC2-01 PAD™ Cream for treatment of psoriasis. Subsequently, the company announced very encouraging Ph2 data on MC2-03 PAD™ Eye Drops for treatment of keratitis associated to dry eye conditions. The company has a strong pipeline of new topical therapies fueled by its PAD™ Technology that enables a new standard of topicals.
“We aim to help people with chronic inflammatory conditions to minimize the daily burden of disease by developing products that provide fast relief of symptoms while being very pleasant to use in daily routines. We know that patients and physicians are waiting for our PAD™ based topicals and we remain agile and focused on execution“, said Mr. Lange.
Mrs. Kappe commented: “The MC2 team has found a long needed solution to a big unmet need for millions of patients that life long have to deal with inflammatory conditions. The PAD™ based topicals have the potential to change the game and become life companions for patients across the globe and I could not be more excited or proud to be part of bringing this paradigm shift to patients.” Mrs. Kappe joins MC2 Therapeutics from Specific Pharma A/S where she most recently served as CEO. Prior to this, Mrs. Kappe held commercial roles at Coloplast A/S and LEO Pharma A/S.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a privately held late clinical-stage emerging pharmaceutical company focused on topical therapies for chronic inflammatory conditions. Using its proprietary PAD™ Technology – a new class of vehicle – MC2 Therapeutics is developing a pipeline of new highly efficacious topical therapies designed for unique patient experiences.
BACK
